Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate and strengthen the body’s immune response against cancer cells.
Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor (TKI) that prevents the growth of cancer cells by blocking the formation of new blood vessels in tumours. It is similar to other approved medications such as Sunitinib (Sutent®) or Axitinib (Inlyta®).
In this trial, researchers will combine these approved treatments with several experimental anti-cancer drugs to see if they are more effective than either treatment alone:
- Favezelimab – Targets a new anti-cancer target called LAG-3
- Bezultifan – Targets a new anti-cancer target called HIF-2-alpha
- Quavonlimab – Targets the established anti-cancer target: CTLA-4
This study will investigate the safety and effectiveness of approved anti-cancer therapies in a number of different combinations to identify if any combinations have a significant advantage over single-agent administration.
Accordingly, you may be randomly enrolled in any one of four treatment groups:
- Pembrolizumab + Quavonlimab + Lenvatinib
- Favezelimab + Pembrolizumab+ Lenvatinib
- Pembrolizumab + Belzutifan + Lenvatinib
- Pembrolizumab + Lenvatinib
- Pembrolizumab + Vibostolimab + Belzutifan
- Clear cell kidney cancer
- Cancer has spread or cannot be removed by surgery
- No prior systemic therapies are permitted
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorNot Given||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreJewish General Hospital||Principal InvestigatorNot Given||LocationMontreal, QC||Trial StatusRecruiting|